![Bernard Pau](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernard Pau active positions
Companies | Position | Start | End |
---|---|---|---|
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Chairman | 16/06/2020 | - |
Chief Operating Officer | 16/06/2020 | - |
Career history of Bernard Pau
Former positions of Bernard Pau
Companies | Position | Start | End |
---|---|---|---|
Biodol Therapeutics SAS
![]() Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Founder | 31/12/2014 | - |
Statistics
International
France | 3 |
Operational
Chairman | 1 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Health Technology |
Biodol Therapeutics SAS
![]() Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Health Technology |
- Stock Market
- Insiders
- Bernard Pau
- Experience